SCHEMBL8228449

SCHEMBL8228449

CC(C)(O)c1cccc(-c2ccn3nc(-c4ccc(F)cc4)cc3c2)c1

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NR4A2 P43354 1/20 0.42
KCNH2 Q12809 1/20 0.42
CYP17A1 P05093 1/20 0.38
CYP3A4 P08684 1/20 0.38
CNR2 P34972 1/20 0.37
CYP11B2 P19099 2/20 0.36
F2 P00734 1/20 0.36
MAPT P10636 3/20 0.35
SYK P43405 1/20 0.35
TGFBR1 P36897 1/20 0.35
CYP11B1 P15538 1/20 0.34
NR3C1 P04150 1/20 0.34
PGR P06401 1/20 0.34
RXRA P19793 1/20 0.34
RXRB P28702 1/20 0.34
MAPK1 P28482 2/20 0.34
HTT P42858 1/20 0.34
NPSR1 Q6W5P4 1/20 0.34
L3MBTL1 Q9Y468 1/20 0.34
LMNA P02545 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8235484 0.88 NR4A2 (0.56) NR4A2KCNH2CYP17A1CYP3A4MAPT
SCHEMBL10475891 0.88 CYP17A1 (0.35) NR4A2KCNH2CYP17A1CYP3A4F2
SCHEMBL8229276 0.79 NR4A2 (0.42) NR4A2MAPTRXRARXRBMAPK1
SCHEMBL10475895 0.79 FYN (0.54) MAPTPGRKDR
SCHEMBL2031842 0.78 KMO (0.44) RXRARXRB
SCHEMBL8236991 0.78 FYN (0.42) NR4A2KCNH2CNR2
SCHEMBL2032459 0.76 FYN (0.46) KCNH2
SCHEMBL2029037 0.76 TDP2 (0.45) NR4A2MAPT
SCHEMBL12543892 0.76 GABRG2 (0.49) CNR2MAPT
SCHEMBL8230154 0.76 TRIM24 (0.42) MAPTMAPK1HTTNPSR1L3MBTL1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2477990-B1 5-PHENYL PYRAZOLOPYRIDINE DERIVATIVES, PREPARATION AND THERAPEUTIC USE THEREOF SANOFI SA (FR) 2014-08-20 EP claimed
US-8618301-B2 5-phenylpyrazolopyridine derivatives, preparation and therapeutic use thereof SANOFI (FR) 2013-12-31 US claimed
US-20130023554-A1 5-PHENYLPYRAZOLOPYRIDINE DERIVATIVES, PREPARATION AND THERAPEUTIC USE THEREOF SANOFI (FR) 2013-01-24 US claimed
EP-2477990-B1 5-PHENYL PYRAZOLOPYRIDINE DERIVATIVES, PREPARATION AND THERAPEUTIC USE THEREOF SANOFI SA (FR) 2014-08-20 EP disclosed
US-8618301-B2 5-phenylpyrazolopyridine derivatives, preparation and therapeutic use thereof SANOFI (FR) 2013-12-31 US disclosed
US-20130023554-A1 5-PHENYLPYRAZOLOPYRIDINE DERIVATIVES, PREPARATION AND THERAPEUTIC USE THEREOF SANOFI (FR) 2013-01-24 US disclosed
EP-2477990-A1 5-PHENYL PYRAZOLOPYRIDINE DERIVATIVES, PREPARATION AND THERAPEUTIC USE THEREOF SANOFI (FR) 2012-07-25 EP disclosed
WO-2011033230-A1 5-PHENYL PYRAZOLOPYRIDINE DERIVATIVES, PREPARATION AND THERAPEUTIC USE THEREOF SANOFI-AVENTIS (FR) 2011-03-24 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130023554-A1 5-PHENYLPYRAZOLOPYRIDINE DERIVATIVES, PREPARATION AND THERAPEUTIC USE THEREOF CBR3, CBR1, OGFR NR4A2 296/4885KCNH2 64/4885CYP17A1 3093/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.